The B4GALT1 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical carcinoma cell line Ca Ski, engineered to disrupt the B4GALT1 gene. This product provides a pool of knockout cells with loss-of-function of beta-1,4-galactosyltransferase, enabling studies of glycosylation in HPV-positive cancer contexts. The polyclonal format offers a practical model for functional genomics, allowing researchers to assess the collective impact of B4GALT1 disruption on cellular processes without the bottleneck of clonal selection.
The Ca Ski cell line is an adherent epithelial model originally established from a cervical epidermoid carcinoma metastasis and harbors an integrated HPV-16 genome, making it a well-characterized system for HPV-positive cervical cancer research. These cells retain key oncogenic drivers associated with HPV-mediated transformation, providing a relevant backdrop for functional dissection of glycosylation-dependent mechanisms in cervical carcinogenesis. The HPV-16 integration and epithelial nature ensure that observations made in this model are directly applicable to the study of cervical tumor biology and the role of viral oncoproteins in remodeling host glycosylation.
B4GALT1 encodes a Golgi-resident glycosyltransferase that catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine residues on glycoproteins and glycolipids, generating LacNAc epitopes. This modification is critical for the synthesis of complex N-glycans and lactose, and is regulated upstream by transcription factors Sp1 and STAT3, as well as by prolactin signaling, while TNF-alpha modulates its expression in inflammatory contexts. The LacNAc structures produced by B4GALT1 serve as ligands for galectin-1 and galectin-3, mediating cell adhesion and signaling events. B4GALT1 activity shapes the N-glycosylation of receptors like EGFR and integrins, influencing downstream pathways, and interacts with alpha-lactalbumin in the mammary gland for lactose synthesis. In the Golgi, B4GALT1 functions within a network of glycosyltransferases, orchestrating the elongation of complex glycans that are central to cell surface recognition and communication.
In HPV-positive cervical cancer, aberrant glycosylation is increasingly recognized as a driver of immune evasion, altered cell adhesion, and metastatic progression. The Ca Ski knockout model provides a controlled system to investigate how B4GALT1-dependent glycan modifications contribute to these processes. Loss of B4GALT1 may disrupt the presentation of galectin ligands on the cell surface, potentially impairing galectin-mediated clustering of glycosylated receptors and affecting signaling cascades that promote tumor cell migration and survival. This model is particularly relevant for studying congenital disorders of glycosylation type IId phenotypes in a cancer context and for exploring how HPV oncoproteins intersect with glycosylation machinery to reshape the cellular glycome, offering insights into the molecular basis of glycosylation-driven oncogenesis.
Researchers can employ this polyclonal knockout cell pool in functional studies of B4GALT1 in HPV-induced oncogenesis, including transwell migration and invasion assays to assess metastatic potential, cell adhesion assays to evaluate galectin-mediated interactions, and lectin blotting with RCA-I to profile galactose-bearing glycans. The cells are suitable for mass spectrometry-based N-glycan profiling to map glycosylation changes, flow cytometry for surface glycan epitope analysis, and RNA-seq to interrogate broader glycosylation pathway alterations. These investigations support drug sensitivity assays for glycan-targeted therapies and enhance understanding of glycosylation??s role in immune recognition. For further details, please contact Ascent Research.
